Ustekinumab more effective and tolerated better than etanercept
Ustekinumab is more effective and causes fewer side effects than etanercept when treating psoriasis, research suggests (New England Journal of Medicine 2010;362:118).
In total, 903 patients with moderate-to-severe psoriasis were randomly assigned to receive ustekinumab 45mg or 90mg (injections at weeks 0 and 4) or etanercept (50mg twice weekly for 12 weeks).
After 12 weeks, the researchers found 56.8% of patients in the etanercept group had achieved a 75% reduction in psoriasis area and severity index — the primary endpoint. By comparison, 73.8% (P<0.001) and 67.5% (P=0.01) of patients in the high- and low-dose ustekinumab groups, respectively, had achieved this reduction.
Adverse events were experienced by 70.0% of patients in the etanercept group, and 66.0% and 69.2% for the low- and high-dose ustekinumab groups, respectively.
Citation: Clinical Pharmacist URI: 10994511
Recommended from Pharmaceutical Press